Meteora Capital
DMAA icon

Meteora Capital’s Drugs Made In America Acquisition Corp DMAA Stock Holding History

Meteora Capital’s Portfolio DMAA Stock Details DMAA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.04M Sell
97,837
-282,462
-74% -$2.99M 0.09% 156
2026
Q1 		$3.99M Buy
+380,299
New +$3.97M 0.29% 97

Other funds holding DMAA

Karpus Investment Management
Karpus Investment Management Pittsford, New York $3.48B AUM 10.49% 1-Year Est. Return
Mizuho Securities USA
Mizuho Securities USA New York $6.2B AUM 35.46% 1-Year Est. Return
Polar Asset Management Partners
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
Glazer Capital LLC
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
Wolverine Asset Management
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
Highbridge Capital Management
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
First Trust Capital Management
First Trust Capital Management Chicago, Illinois $1.72B AUM 70.66% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
Westchester Capital Management (New York)
Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return
Aristeia Capital
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return

Meteora Capital's DMAA Position: Q2 2026 in Review

Meteora Capital reduced its Drugs Made In America Acquisition Corp (DMAA) stake by 74% in Q2 2026, selling an estimated $2.99M and leaving 97,837 shares worth $1.04M. The position accounts for 0.09% of the portfolio, ranked #156.

Meteora Capital first reported a position in DMAA in Q1 2026 and has held it in 2 quarters since. The position peaked at $3.99M in Q1 2026. 23 funds tracked by Wall St. Rank hold DMAA as of Q2 2026.

  • Meteora Capital held 97,837 shares of Drugs Made In America Acquisition Corp worth $1.04M as of Q2 2026.
  • Meteora Capital sold 282,462 Drugs Made In America Acquisition Corp shares in Q2 2026, an estimated $2.99M.
  • Drugs Made In America Acquisition Corp made up 0.09% of Meteora Capital's portfolio in Q2 2026, its #156 holding.
  • Meteora Capital first reported a position in Drugs Made In America Acquisition Corp in Q1 2026 and has held it in 2 quarters since.
  • Meteora Capital's Drugs Made In America Acquisition Corp position peaked at $3.99M in Q1 2026.
  • 23 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp as of Q2 2026.

Based on Meteora Capital's 13F filing for Q2 2026, filed 14 Aug 2026.